Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease
| Autor: | Anat Mirelman, Avi Orr-Urtreger, Nir Giladi, Lorraine N. Clark, Helen Mejia-Santana, Rachel Saunders-Pullman, Laurie J. Ozelius, Roy N. Alcalay, Christina Palmese, Deborah Raymond, Susan B. Bressman, Elise Caccappolo, Karen Marder |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Heterozygote Parkinson's disease Postural instability Neuropsychological Tests Protein Serine-Threonine Kinases Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Article Physical medicine and rehabilitation Medicine Humans Ashkenazi Jewish Aged business.industry Neuropsychology Heterozygote advantage Parkinson Disease Middle Aged medicine.disease LRRK2 nervous system diseases Neurology Jews Cognitive screening Physical therapy Female Neurology (clinical) Gait difficulty Geriatrics and Gerontology business Psychomotor Performance |
| Zdroj: | Parkinsonismrelated disorders. 21(2) |
| ISSN: | 1873-5126 |
| Popis: | Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests.To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery.We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n = 236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n = 112) were evaluated with the entire battery. Tel Aviv participants (n = 124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS).Carriers had longer disease duration (p0.001) and were more likely to manifest the PIGD phenotype (p = 0.024). In adjusted regression models, carriers performed better than non-carriers in Stroop Word Reading (p0.001), Stroop Interference (p = 0.011) and Category Fluency (p = 0.026).In AJ-PD, G2019S mutation status is associated with better attention (Stroop Word Reading), executive function (Stroop Interference) and language (Category Fluency) after adjustment for PIGD motor phenotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect